



# Pauline Allen Gill Center for Cancer and Blood Disorders

The Pauline Allen Gill Center for Cancer and Blood Disorders at Children's Medical Center Dallas is a **world-class pediatric treatment center** recognized nationally for exceptional clinical care, leadership in pediatric cancer research and academic excellence. All pediatric hematology/oncology physicians provide clinical care at Children's Health<sup>SM</sup> and are faculty members at UT Southwestern.



## 2018 Investigator-Initiated Phase I/II and Non-Consortium Therapeutic Translational Research Trials

# of open trials

- 8** Leukemia/Lymphoma trial
- 6** Solid tumors trial
- 4** CNS tumor trial
- 3** Transplants
- 3** Non-disease specific trial

The team has more than

# 250


physicians, nurses, advanced practice providers, social workers, child life specialists, nutritionists and many others.



The Pauline Allen Gill Center is the largest childhood cancer and blood disorders center in North Texas; **we treat approximately 350 new patients each year.**



We treat **1 out of 5** children in Texas diagnosed with cancer.



Children's Health is the **only pediatric cancer program affiliated with the UT Southwestern Harold C. Simmons Comprehensive Cancer Center**, as the only National Cancer Institute-

designated comprehensive cancer center in North Texas, we push to discover new treatments and offer patients the ability to participate in the broadest possible range of clinical trials, giving access to potential therapies not available at other facilities.

## Highlighted Clinical Trials:

### Next Generation Tropomyosin Receptor Kinase (TRK) Inhibition for TRK Fusion Cancers

- A Phase I/II Study of the TRK Inhibitor LOXO-195 in adult and pediatric subjects with previously treated NTRK Fusion Cancers

### CAR-T Cell Studies

- A Phase II, single arm, multicenter open label trial to determine the safety and efficacy of tisagenlecleucel in pediatric patients with relapsed or refractory mature B-cell non-Hodgkin lymphoma (NHL)
- A phase I, open label, non-comparative, study to evaluate the safety and the ability of UCART19 to induce molecular remission in pediatric patients with relapsed/refractory B-cell acute lymphoblastic leukemia

To learn more, visit [childrens.com/cancer](http://childrens.com/cancer)



Specialty care provided by UT Southwestern physicians